• Promising interim data in the phase I study
• Raised a net of MSEK 73 and received a loan commitment of MSEK 20
• Awaiting the final read-out, we keep our fair value at SEK 10.81 per share
In Lipum’s Q2 report, CEO Ola Sandborgh repeated that he expects to complete
the phase I study with SOL-116 during the second half of 2024. Interim results
indicate that the study will meet its primary safety and tolerability
endpoints. The drug candidate has also shown expected and preferred
pharmacokinetics. Currently, the last group including rheumatoid arthritis
patients is about to be concluded.
We maintain our model assumptions until the phase I study is completed.
Therefore, we keep our risk-adjusted fair value at SEK 10.81 per share for
now.